Open Access

Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries

  • Zaino Petersen1Email author,
  • Bronwyn Myers1, 2,
  • Marie-Claire van Hout3,
  • Andreas Plüddemann1 and
  • Charles Parry1, 4
Harm Reduction Journal201310:13

DOI: 10.1186/1477-7517-10-13

Received: 1 October 2012

Accepted: 13 August 2013

Published: 19 August 2013

Abstract

Background

About a third of the global HIV infections outside sub-Saharan Africa are related to injecting drug use (IDU), and this accounts for a growing proportion of persons living with HIV. This paper is a response to the need to monitor the state of the HIV epidemic as it relates to IDU and the availability of HIV treatment and harm reduction services in 21 high epidemic countries.

Methods

A data collection form was designed to cover questions on rates of IDU, prevalence and incidence of HIV and information on HIV treatment and harm reduction services available to people who inject drugs (PWID). National and regional data on HIV infection, IDU in the form of reports and journal articles were sought from key informants in conjunction with a systematic search of the literature.

Results

Completed data collection forms were received for 11 countries. Additional country-specific information was sourced via the literature search. The overall proportion of HIV positive PWID in the selected countries ranged from 3% in Kazakhstan to 58% in Vietnam. While IDU is relatively rare in sub-Saharan Africa, it is the main driver of HIV in Mauritius and Kenya, with roughly 47% and 36% of PWID respectively being HIV positive. All countries had antiretroviral treatment (ART) available to PWID, but data on service coverage were mainly missing. By the end of 2010, uptake of needle and syringe programmes (NSP) in Bangladesh, India and Slovakia reached the internationally recommended target of 200 syringes per person, while uptake in Kazakhstan, Vietnam and Tajikistan reached between 100-200 syringes per person. The proportion of PWID receiving opioid substitution therapy (OST) ranged from 0.1% in Kazakhstan to 32.8% in Mauritius, with coverage of less than 3% for most countries.

Conclusions

In order to be able to monitor the impact of HIV treatment and harm reduction services for PWID on the epidemic, epidemiological data on IDU and harm reduction service provision to PWID needs to be regularly collected using standardised indicators.

Keywords

Injecting drug use People who inject drugs Harm reduction HIV prevention

Background

Globally there are approximately 15.9 million people who inject drugs (PWID), with around 80% of PWID living in low and middle income countries (LMIC) [1]. The continued high prevalence of injection drug use (IDU) is cause for concern because of the strong association between IDU and risk for Human Immunodeficiency Virus (HIV) transmission. This association is largely due to the sharing of drug paraphernalia with other PWID, with needle sharing accounting for about one tenth of new HIV infections globally and almost a third of all new HIV infections outside sub-Saharan Africa [2]. Regions with particularly high rates of new HIV infections among PWID include Eastern Europe and Central Asia as well as East and South-East Asia [3].

In contrast, there has been a decline in HIV incidence in the USA and Western Europe [4]. This decline has been spurred on by behaviour changes among at-risk populations (including PWID) as well as improved access to HIV treatment and harm reduction services for these populations [57]. However, access to adequate HIV treatment and harm reduction services for PWID varies from country to country. Earlier work has shown that many of the countries with high rates of new HIV infections among PWID fail to provide PWID with access to the recommended comprehensive package of evidence-based HIV treatment and harm reduction services [8, 9]. In particular, limited availability of antiretroviral therapy (ART) and harm reduction services (such as needle and syringe programmes (NSP) and opioid substitution therapy (OST)) is a major barrier to efforts to limit HIV transmission amongst PWID and their injecting and sexual partners [1012].

Even in countries that report the availability of core HIV treatment and harm reduction services for PWID, earlier work has highlighted that ART, NSP and OST service coverage is generally below the minimum threshold needed to adequately prevent new HIV infections among PWID [1214]. Concerns about the poor availability and limited coverage of these services have led to continued calls for the introduction of and, where present, scaling up of the provision of these services. Although these services are especially important for countries where the HIV epidemic is concentrated amongst PWID, they are also vital for countries where IDU is an emerging public health concern [1113]. In order to guide effective country-level responses to these issues, updated information is needed on IDU rates, prevalence of HIV among PWID, the types of treatment and harm reduction services provided to PWID living with HIV and the degree of service coverage. Although global reviews of the epidemiology of HIV among PWID [2] and HIV service coverage [12] have been conducted in the past five years, several LMICs with emerging HIV epidemics among PWID have not had data available to contribute to these reviews. For other high epidemic countries, it is unclear whether the prevalence of HIV and the extent to which HIV treatment and harm reduction services are available for PWID have changed since the time of the last review [2].

This paper is in response to this need for updated data on HIV prevalence and harm reduction service provision among PWID for 21 LMICs with either high or emerging HIV epidemics among PWID. More specifically, this paper describes the (i) prevalence of IDU; (ii) the prevalence of HIV among PWID; (iii) the provision of NSP, OST and ART to PWID; and (iv) the extent to which NSP, OST and ART are provided relative to the size of the IDU population in the 21 selected countries.

Methods

Sample description

Twenty-one countries were chosen by the Steering Committee of the International Reference Group to the United Nations on IDU and HIV to participate in this study. These countries were selected based on the state of the HIV epidemic in these countries, resource needs and availability of partner organizations to support efforts to introduce and/or scale up HIV treatment and harm reduction services. Selected countries included: Afghanistan, Bangladesh, Belarus, China, India, Indonesia, Kenya, Kazakhstan, Kyrgyzstan, Lithuania, Mauritius, Moldova, Myanmar, Nepal, Nigeria, Pakistan, Russia, South Africa, Tanzania, Ukraine and Vietnam.

Data collection

A data collection form was used to collect national and regional estimates of the population prevalence of IDU, prevalence of HIV, availability and coverage of HIV treatment (the provision of ART) and harm reduction services for PWID (the provision of NSP/OST in the 21 countries between June 2010 and June 2011). These forms were completed by key contacts who were experts in IDU and HIV in the selected countries. The forms were also used by the research team to guide data extraction from country reports and relevant publications. The content of this data collection form was informed by the Steering Committee of the Reference Group, the Secretariat to the UN Reference Group and prior data collection exercises conducted by the Reference Group [2, 11]. In addition, key contacts were asked to provide supporting evidence in the form of reports, publications and presentations where these were available. After only receiving completed data collection forms from 11 of the 21 countries and realizing that recent 2010-2011 information on these key indicators was not yet available for many of the selected countries, we undertook a literature search using Sciencedirect, PubMed, Google, and Google scholar and Ebscohost. The websites of international agencies with a presence in these countries (e.g. UNODC, UNAIDS and WHO), and the conference proceedings of recent international meetings on HIV and drug use to identify recent reports and publications on the epidemiology of IDU and HIV in the selected 21 countries. This information was searched for between January 2011 and January 2012, and only the most updated information (from 2010 and later) was included. Literature was further sifted according to whether it contained information on the 21 selected countries and whether it described the main prompts on the data collection form (IDU and HIV prevalence, as well as OST, NSP and ART availability). Data were extracted from these reports, presentations and publications using the aforementioned data collection form. Information from the literature was checked by three staff members, with one member doing the search, and two others cross checking and updating information where necessary. Reference group members in the diferent countries were alo given the opportunity to update findings.

Results

Prevalence of IDU and HIV among PWID

Of the 21 participating countries, the Russian Federation and the Ukraine were countries identified with the highest rates of reported IDU, with roughly 2 million (2% of adult the population) and 425000 (1.3% of the adult population) injecting drugs respectively (Table 1). In the selected countries, the overall proportion of PWID living with HIV ranged from 3% in Kazakhstan to 58% in Vietnam (Table 1). Taking the midpoint in cases where a range was given, the average proportion of PWID living with HIV across the 19 countries where data were available was almost 22%. However country-level estimates sometimes mask regional concentrations of HIV among PWID. For example, a recent UNAIDS publication reported HIV prevalence in St Petersburg, Russia, to have doubled in the past five years, with approximately 60% of PWID in this city living with HIV [6].
Table 1

Estimated population size, proportion of population that inject drug and the number of HIV-positive drug users*

Country

Population (all ages)

Population (15-64 years)

No of PWID1(range)

No. of PWID that are HIV+* (range)

% of HIV+ PWID**

Afghanistan

29,835,392

16,492,454

19,000-25,000

1,330-1,750

7

Bangladesh

158,570,535

96.847,950

20,000-40,000

1,600-3,200

8

Belarus

9,557,552

6,870,907

69,200-83,400

9,480-11,425

13.7

China

1,336,718,015

983,280,460

642,000

44,940-83,460

7-13

India

1,210,193,422

771,476,660

177,000-180,000

16,284-16,560

9.2

Indonesia

237.6 million

163,367,691

222,500

60,075

27

Kenya

41,070,934

22,634,399

30,000

10,800-12,900

36-43

Kazakhstan

16,455,000

11,028,216

186,000

5,580

3

Kyrgyzstan

5,587,443

3,656,055

_______

_______

_______

Lithuania

3.2 million

2,475,902

5,458

1,250

22.9

Mauritius

1,286,340

921,618

10,000

4,740

47.4

Moldova

4,314,377

3,193,494

25,000

4,450

17.8

Myanmar

53,999,804

36,442,403

75,000

27,750-28,500

37-38

Nepal

29,391,883

17,951,875

28,500

5,415

19

Nigeria

155,215,573

86,830,770

________

_______

8.918

Pakistan

187,342,721

113,072,889

125,000

26,250

21

Russia

142,905,208

99,594,130

2 million

_______

_______

South Africa

49,054,031

32,259,360

67,0001

12,998

19.4

Tanzania

42,746,620

23,547,672

25,000-50,000

10,500-21,000

42

Ukraine

45,134,707

31,956,390

325000-425000

74,425-97,325

22.9

Vietnam

90,549,390

62,721,185

142,000

45,440-82,360

32-58

1 calculated from a national 2008 Survey.

*An estimation of the number of PWID that were HIV positive by 2010. Where updated data was not available the latest reported prevalence was used, including periods 2006-2010. **Calculated at the midpoint of the range where applicable. ______ Data is not available.

HIV prevalence among PWID in one region of Afghanistan was found to have increased from 3% in 2006 to 7% by 2011 (Table 1). While pilot harm reduction programmes are available (NSP’s and drug rehabilitation centres), a scale-up of these interventions is urgently required for IDU’s in order to prevent a future HIV epidemic [15, 16]. Whilst Bangladesh experienced an increase in the rates of HIV between 2001 and 2009, one area (Dhaka) where harm reduction programmes are available experienced a decrease in the rates of new HIV infections. Here the availability of harm reduction programmes for PWID resulted in a reduction in HIV prevalence from 7% in 2007 to 5.3% in 2011 [6]; (Table 1).

While IDU is relatively rare in sub-Saharan Africa, IDU appears to act as the main driver of HIV in Mauritius, with roughly 47% of PWID being HIV positive. Other available research in sub-Saharan Africa shows a high HIV prevalence among PWID in Kenya (36%), Zanzibar in Tanzania (26%), and the Kano region in Nigeria (10%) [5]; (Table 1).

Availability of core HIV treatment (ART) and harm reduction (NSP/OST) services for PWID

All 21 countries reported that ART was available to PWID living with HIV (Table 2). However, most countries collected data on the number of services providing ART to the general public rather than the number of services providing ART to PWID specifically. Of concern is the large number of countries with high prevalence rates of HIV among PWID that do not know the proportion of HIV-positive PWID receiving ART. Even where data were available, the estimated proportion of PWID living with HIV and using ART was low, ranging from 0.6% in Afghanistan to 22% in Bangladesh.
Table 2

Availability and coverage of ART among PWID in 2010-

Country

ART availability 2011

Est. no. of HIV positive pop receiving ART3

No. of HIV+ PWID

Est. no. of HIV+ PWID receiving ART

Afghanistan

yes

---------

1330-1750

12

Bangladesh

yes

1725

1600-32005

353 (Dec 09)

Belarus

yes

2,614

_______

_______

China

yes

86,122

169120-314080

12 762

India

yes

424,802

16284-16560

1900

Indonesia

yes

19,572

_______

_______

Kenya

yes

432,621*

10800-12900

_______

Kazakhstan

yes

1,336

5208

182

Kyrgyzstan

yes

548

_______

115

Lithuania

yes

_______

1250

62

Mauritius

yes

646

4740

530

Moldova

yes

1,237

4450

446

Myanmar

yes

29,825

27750-28500

_______

Nepal

yes

4,867

8%

_______

Nigeria

yes

359,181P

8.9%18

_______

Pakistan

yes

1,892

26,250

_______

Russia

yes

79,430

________

_______

South Africa

yes

1,389,865*

1920

_______

Tanzania

yes

258,069

10500-21000

Unknown

Ukraine

yes

22,697

74425-97325

1732 (Jan 2011

Vietnam

yes

49,492

45440-82360

_______

* Estimated no of “general population” receiving ART.

______ Data are not available.

In terms of the availability of HIV prevention services for PWID, in 2011 NSPs were available in 20 of the 21 countries examined, but the number of NSP sites varied per country (Table 3). In countries where rates of IDU were low (such as South Africa) introducing NSPs is often not publicly accepted. For example one NSP site has been established in South Africa, however this service is affiliated to an organization providing services to men who have sex with men (MSM), which indicates limited reach to PWID who are not MSM. While Mauritius has some NSPs and Tanzania has pilot programmes, these services are unavailable in Kenya and Nigeria (Table 3).
Table 3

Availability and coverage of needle and syringe programs (NSP) in 2010-11

Country

NSP availability

No. of NSP sites nationally

No. of PWID served in last 12 months

No. of syringes per PWID distributed in 1 year (Jan-Dec 2010)

Afghanistan

yes

9

_______

34.7

Bangladesh

yes

120

26000

214.4

Belarus

yes

_______

_______

46.5

China

yes

1052

39,500

18.9

India

yes

261

135000

228.2

Indonesia

yes

_______

_______

10.2

Kenya

no

_______

_______

_______

Kazakhstan

yes

168

73,252

176.4

Kyrgyzstan

yes

_______

_______

_______

Lithuania

yes

12

429

_______

Mauritius

yes

52

6000 p/y

51.9

Moldova

yes

29

_______

65.8

Myanmar

Yes

40 (2008)

13368

91.7

Nepal

Yes

9

_______

56.5

Nigeria

No

_______

_______

_______

Pakistan

Yes

15

1500

_______

Russia

Yes

69

_______

_______

South Africa

Yes

1

_______

_______

Tanzania

Yes

1 (new , Jul2011)

1048

_______

Ukraine

Yes

1633

174796

62.4

Vietnam

Yes

_______

_______

140.6

______ Data are not available.

In addition, information on the degree of service coverage provided by available NSPs (in terms of the total number of needles distributed per annum and the number of needles provided to each PWID) was unavailable for 9 of the 21 countries (Table 3). For the 13 countries with available data on the number of needles distributed per year, most countries (10) reported low levels of NSP coverage (Table 3). In other words, they provide fewer than 100 needles and syringes per PWID per year [17]. However by the end of 2010, NSP coverage in two countries (Bangladesh and India) had reached the internationally recommended target of 200 syringes per PWID with coverage in Kazakhstan and Vietnam having reached medium levels; that is between 100-200 syringes per PWID per year [18].

OST as treatment for opioid dependence and as a means of reducing risky injection practices was available in 17 of the 21 selected countries (Table 4). Of the countries that provided OST, methadone maintenance therapy (MMT) was recorded as the most widely used treatment modality.
Table 4

Availability and coverage of opioid substitution therapy (OST) 2010-11

Country

OST availability

No. of OST sites nationally

MMT/BMT

% of PWID receiving OST in last 12 months, Dec 2010

Afghanistan

Yes

_______

_______

0.4

Bangladesh

Yes

1

MMT

0.3

Belarus

Yes

_______

_______

0.9

China

Yes

928

MMT

28.4

India

Yes

65

BMT

3

Indonesia

Yes

9

_______

2.4

Kenya

_______

_______

_______

_______

Kazakhstan

Yes

10

MMT

0.1

Kyrgyzstan

_______

_______

_______

_______

Lithuania

Yes

21

MMT&BMT

_______

Mauritius

Yes

16

MMT

32.8

Moldova

Yes

8

MMT

1.4

Myanmar

Yes

10

MMT

1.5

Nepal

yes

8

_______

1.2

Nigeria

yes

_______

_______

_______

Pakistan

No

_______

_______

_______

Russia

No

_______

_______

_______

South Africa

Yes

_______

BMT&MMT

_______

Tanzania

Yes

1 new Feb 2011

MMT

0.7

Ukraine

Yes

125

MMT and BMT

2.1

Vietnam

Yes

8

_______

1.3

_______Data are not available.

Information on OST provision was not available for six of the 21 countries (Afghanistan, Belarus, Indonesia, Kenya, Kyrgyzstan, and Vietnam). Two countries (Russia and Pakistan) reporting no OST service provision, and with either MMT or buprenorphine maintenance therapy (BMT) available in 13 countries (Table 4). Furthermore, OST service coverage is generally poor in most of the countries reporting OST sites, with less than 3% of PWID in 11 of the 21 countries with available data. For example, South Africa has had BMT available for a few years in the private sector and recently MMT has also become available in this sector, but currently there are no public OST sites available. More specifically, the proportion of PWID receiving OST ranges from 0.1% in Kazakhstan to 32.8% in Mauritius. In addition, two countries (Bangladesh and Tanzania) have only recently started providing OST, with one pilot site available in each country.

Discussion

This paper details the prevalence of IDU and HIV, the availability of HIV treatment (ART) and harm reduction (NSP/OST) services across 21 countries with either high or emerging HIV epidemics among PWID, and efforts to scale up service coverage to PWID. The increasing rates of IDU and HIV among IDU remain concerning. Varying rates of HIV prevalence among PWID and varying levels of HIV treatment and harm reduction service coverage have been noted.

First, this study found that countries surveyed vary with regards to IDU trends, with some having a very high prevalence of IDU, while it is an emerging trend in others. Specifically, across the 21 countries surveyed, the Russian Federation and the Ukraine are the countries with the highest prevalence of IDU, while most African countries have comparatively lower proportions of PWID. Despite this, IDU is a cause for concern in African countries, which already have generalized HIV epidemics. Failure to address IDU and HIV risk among PWID in this region will impact negatively on efforts to prevent new HIV infections and curtail the epidemic. Between one fifth and a quarter of PWID across the selected countries are living with HIV. The average proportion of PWID who are HIV positive is just under 22% across the 19 countries where data were available.

Second, the paper also highlights the poor coverage of ART services for PWID, across the 21 countries. The proportion of PWID who are HIV positive and who receive ART is very low (less than 12% with the exception of Bangladesh). This could be because they are still healthy (CD4 counts that are still high), however, this information is lacking and in light of recent reports [19], it is more likely that it is because of barriers to accessing ART for PWID. The lack of updated data with regards to IDU and HIV services to PWID is a matter of concern for many of the 21 countries. A large number of countries with high prevalence rates of HIV among PWID are not aware of the proportion of HIV positive PWID who are receiving ART. This is a major concern as ART use can help decrease risk of transmission among PWID and also their sexual partners. Data on ART service coverage disaggregated by IDU is increasingly necessary, especially in countries with a high prevalence of HIV among IDU, but also for countries where IDU is an emerging problem. This data could serve as a baseline for informing the development, implementation and scaling up of HIV treatment services for PWID.

Third, we noted that these 21 countries also vary in the extent to which they provide harm reduction services to PWID, with some countries having established harm reduction services for PWID, and others only beginning to pilot harm reduction programs, due to the rising prevalence of IDU. NSP, in particular, is a fairly new phenomenon in many of the selected countries, with some countries only having one or two pilot NSP sites to date. While most of the selected countries now have NSP available, the extent to which PWID have access to such programmes is questionable. In countries where NSPs are available, only two out of the 21 countries (Kazakhstan and Vietnam) provided medium coverage (between 100-200 syringes per IDU per year), and only two countries provided high coverage (Bangladesh and India). These findings suggest that much more needs to be done to bring these NSPs to scale and help prevent new HIV infections. Barriers to the provision of clean syringes to PWID and uptake of services also need to be addressed in order to improve harm reduction practices.

While many of the selected countries had OST available to PWID, the number of sites per country was low with very few PWID having access to such services. While not all PWID (particularly those injecting amphetamine type stimulants (ATS) require OST, OST coverage still appears to be low (less than 3%) although some exceptions were noted, namely China and Mauritius. A recent report also noted the emergence of amphetamine type stimulants (ATS) in many countries, and the need for harm reduction services for people who inject ATS [20]. This report highlights the lack of information on ATS, as most of the countries do not routinely differentiate between amphetamine and opioid injection. This lack of knowledge affects service planning, as countries have no baseline information that can be used to assess the effectiveness of efforts to scale up services.

The overriding limitation of these data is that data across countries are not collected in a uniform way, with updated information available for some countries only. Eleven of the 21 countries provided data by completing the data collection form, but even for these countries there were many gaps in terms of programmatic evidence, simply because such data are not readily available. And, while the latest progress report on the Global HIV/AIDS response indicates a dramatic improvement in evidence-based HIV prevention, even in this report the ‘evidence’ for many countries is either lacking or fragmented. This data collecting exercise whilst highlighting the lack of specific HIV-related harm reduction services for PWID in some countries, offers a benchmark for improving service coverage in response to emerging injecting trends and rates of HIV.

Conclusion

Despite some limitations, this paper points to the need for countries, through UNODC offices or other agencies such European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), to routinely collect timely data on IDU and non-IDU trends and related HIV rates using a standard data collection form and indicators, with similar time-frames for all countries. PWID remain a high risk cohort for new HIV transmissions. Standardised and routine data collection on IDU and HIV would allow policy makers, researchers and programme planners to monitor the impact of scaling up HIV treatment (ART) and harm reduction (NSP/OST) services for PWID. It remains evident that such services should be widely available to PWID.

Abbreviations

ART: 

Antiretroviral Therapy

ATS: 

Amphetamine Type Stimulants

HIV: 

Human Immunodeficiency Virus

IDU: 

Injection Drug Use

MSM: 

Men who have sex with men

NSP: 

Needle and Syringe Programmes

OST: 

Opioid Substitution Therapy

PWID: 

People Who Inject drugs.

Declarations

Acknowledgements

Financial support for this initiative was provided by the United Nations on Drugs and Crime (UNODC).

Authors’ Affiliations

(1)
Medical Research Council, Alcohol and Drug Abuse Research Unit
(2)
Department of Psychiatry and Mental Health, University of Cape Town, Groote Schuur Hospital, Observatory
(3)
School of Health Sciences; Waterford Institute of Technology
(4)
Department of Psychiatry, University of Stellenbosch

References

  1. IHRA: The Global State of Harm Reduction 2010, key issues for broadening the response (report). 2010, London UK: International Harm Reduction Association
  2. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee S: Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review’. Lancet. 2007, 372: 1733-1745.View Article
  3. International Harm Reduction Development Program: Harm reduction developments 2008: countries with injection-driven HIV epidemics. 2008, New York, USA: Open Society Institute, Figures: Eastern Europe and Central Asia as of 2007 (Russia: 2006); Indonesia and Malaysia: 2006; China and Vietnam: 2005
  4. UNAIDS: Report on the global AIDS epidemic, 2010. 2010, Geneva: UNAIDS
  5. UNAIDS: UNAIDS:world AIDS day report, 2011. 2011, Geneva: UNAIDS
  6. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JS: Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009, 338: b1649-10.1136/bmj.b1649.PubMed CentralView ArticlePubMed
  7. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010, 376: 532-539. 10.1016/S0140-6736(10)60936-1.PubMed CentralView ArticlePubMed
  8. Wolfe D, Carrieri MP, Shepard D: Treatment and care for injecting drug users With HIV infection: A review of barriers and ways forward. Lancet. 2010, 376: 355-366. 10.1016/S0140-6736(10)60832-X.View ArticlePubMed
  9. Ball A, Beg M, Doupe A, Weiler G: Evidence for action: a critical tool for guiding policies and programmes for HIV prevention, treatment and care among injecting drug users (editorial). International Journal of Drug Policy. 2005, 16 (1): 1-6. 10.1016/j.drugpo.2004.12.001.View Article
  10. Wood E, Montaner JS, Bangsberg DR, Tyndall MW, Strathdee SA, O’Shaughnessy MV, Hogg RS: Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003, 17: 2419-2427. 10.1097/00002030-200311210-00003.View ArticlePubMed
  11. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA: Reference group to the UN on HIV and injecting drug use: (2010): HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2009, 375: 1014-1028.View Article
  12. WHO, UNODC and UNAIDS: Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2009, Geneva: World Health Organization
  13. Donoghoe MC, Verster A, Pervilhac C, Williams P: Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): towards consensus and improved guidance (Discussion). International J of Drug Policy. 2008, 19 (1): 5-14.View Article
  14. WHO, UNAIDS, UNICEF: 2011 Progress Report. Global HIV/AIDS response: epidemic update and health sector progress toward universal access. 2011, Geneva: UNAIDS
  15. UNGASS Country Report Afghanistan: Reporting period: January 2008 to December 2009. 2010, Islamic Republic of Afghanistan: National AIDS control Program
  16. Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, Earhart KC: HIV, hepatitis C and hepatitis B infections and associated risk behavior in injection drug users, Kabul< Afghanistan. J Public Health. 2007, 13 (9): 1327-1331.
  17. Bryant J, Topp L, Hopwood M, Iversen J, Treloar C, Maher L: Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south-east Sydney. Drug Alcohol Rev. 2010, 29 (4): 364-370. 10.1111/j.1465-3362.2009.00154.x.View ArticlePubMed
  18. UNODC Concept Note: Reducing drug demand and HIV in Afghanistan. Vienna Austria: UNODC, Time Frame: June 2010 – July 2012
  19. Myers B, Petersen Z, Pithey A, Pasche S, Dada S: A report developed by the Secretariat to the reference group to the United Nations on HIV and injecting drug use. Barriers to antiretroviral use among people who inject drugs: a systematic review. 2011, South Africa: Medical Research Council
  20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Amphetamine – a European union perspective in the global context. 2011, Portugal: EMCDDA

Copyright

© Petersen et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement